Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Translational Lung Cancer Research|February 17, 2025
Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case reportJulie Lasvergnas, Isabelle Monnet, Jean-Bernard Auliac, et al.
Targeted Oncology|September 21, 2022
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French StudyAssya Akli, Nicolas Girard, Vincent Fallet, et al.
Journal of Cancer Research and Therapeutics|December 13, 2022
Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 studyNicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, et al.
Translational Lung Cancer Research|July 11, 2026
End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysisGaspard Naulleau, Gary Birsen, Pascal Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2019
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French studyCamille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, et al.
Targeted Oncology|November 15, 2023
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Bulletin Du Cancer|June 19, 2022
When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric studyAnne-Pascale Meert, Anne-Claire Toffart, Muriel Picard, et al.
Targeted Oncology|March 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS StudyJean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Pageof 1